title: [Therapeutic approaches for macular telangiectasia type 2: status quo and perspectives].
abstract: Macular telangiectasia type 2 is characterized by neurodegenerative as well as vascular and retinal alterations. Previous therapeutic approaches mainly targeted the vascular changes; however, this did not prove to be beneficial except for secondary neovascularization which may be successfully treated with intravitreal vascular endothelial growth factor inhibitors. As the natural history of the disease is primarily characterized by the neurodegenerative processes, new therapeutic strategies, such as neuroprotective agents are already being explored in clinical trials.
authors.affiliation: Universitäts-Augenklinik Bonn, Ernst-Abbe-Str. 2, 53127, Bonn, Deutschland, peter.issa@ukb.uni-bonn.de.
authors.forename: F G
authors.initials: FG
authors.lastname: Holz
authors.forename: T F C
authors.initials: TF
authors.lastname: Heeren
authors.forename: E
authors.initials: E
authors.lastname: Krüger
authors.forename: M
authors.initials: M
authors.lastname: Zeimer
authors.forename: D
authors.initials: D
authors.lastname: Pauleikhoff
authors.forename: P
authors.initials: P
authors.lastname: Charbel Issa
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006801:Humans; D019636:Neurodegenerative Diseases / Q000175:diagnosis / Q000188:drug therapy*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D058456:Retinal Telangiectasis / Q000175:diagnosis / Q000188:drug therapy*; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D018696:Neuroprotective Agents